Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 576,400 shares, a decrease of 13.2% from the January 15th total of 664,400 shares. Based on an average daily volume of 462,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 21.8% of the shares of the stock are short sold.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its position in shares of Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock worth $26,000 after acquiring an additional 622 shares during the last quarter. AlphaMark Advisors LLC boosted its position in shares of Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after acquiring an additional 1,000 shares during the last quarter. Golden State Wealth Management LLC bought a new position in shares of Aligos Therapeutics during the fourth quarter worth $107,000. Northern Trust Corp bought a new position in shares of Aligos Therapeutics during the fourth quarter worth $205,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after purchasing an additional 2,306 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $23.67 on Monday. The firm has a fifty day moving average price of $32.79 and a 200 day moving average price of $20.10. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $46.80. The firm has a market cap of $84.93 million, a price-to-earnings ratio of -1.78 and a beta of 2.45.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).